AngioDynamics Inc (ANGO) Stock
NSQ · ANGO
15.50
Fundamentals
Market cap
$640.24M
Price / Earnings ratio
-17.2x
Price / Sales ratio
2.0x
Price / Book ratio
3.7x
Return on assets
-12.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
NeutralANGOAugust 13, 2026
Zacks Investment ResearchNeutral
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
ANGO

MarketBeat
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
NeutralANGOAugust 11, 2026
MarketBeatNeutral
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
ANGO

Zacks Investment Research
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
NeutralANGOAugust 6, 2026
Zacks Investment ResearchNeutral
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
ANGO

Zacks Investment Research
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
NeutralANGOAugust 6, 2026
Zacks Investment ResearchNeutral
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
ANGO
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
2026
384M254M127M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
2026
336M222M111M0
Revenue to Profit
2026$320.2M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-36.7M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
NeutralANGOAugust 13, 2026
Zacks Investment ResearchNeutral
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
ANGO

MarketBeat
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
NeutralANGOAugust 11, 2026
MarketBeatNeutral
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
ANGO

Zacks Investment Research
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
NeutralANGOAugust 6, 2026
Zacks Investment ResearchNeutral
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
ANGO

Zacks Investment Research
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
NeutralANGOAugust 6, 2026
Zacks Investment ResearchNeutral
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
ANGO

Zacks Investment Research
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
NeutralANGOAugust 6, 2026
Zacks Investment ResearchNeutral
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
ANGO

Business Wire
AngioDynamics to Participate in Upcoming Investor Conferences
NeutralANGOJuly 28, 2026
Business WireNeutral
AngioDynamics to Participate in Upcoming Investor Conferences
ANGO

Zacks Investment Research
AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
NeutralANGOJuly 15, 2026
Zacks Investment ResearchNeutral
AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
ANGO

MarketBeat
AngioDynamics Q4 Earnings Call Highlights
NeutralANGOJuly 14, 2026
MarketBeatNeutral
AngioDynamics Q4 Earnings Call Highlights
ANGO

Zacks Investment Research
AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates
NeutralANGOJuly 14, 2026
Zacks Investment ResearchNeutral
AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates
ANGO

Business Wire
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
NeutralANGOJuly 14, 2026
Business WireNeutral
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
ANGO
About AngioDynamics Inc
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
SectorHealthcare
IndustryMedical Instruments & Supplies
Employees632
CEOMr. James C. Clemmer
IPO DateMay 27, 2004
HeadquartersLatham, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. James C. Clemmer | CEO, President & Director | 1964 |
| Mr. Stephen A. Trowbridge | Executive VP & CFO | 1974 |
| Mr. Lawrence T. Weiss | Senior VP, Chief Legal Officer & Corporate Secretary | 1970 |
| Mr. Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | 1969 |
| Ms. Laura Piccinini | Senior VP and GM of Cardiovascular & International | 1969 |
| Mr. Saleem M. Cheeks | Vice President of Communications | — |
| Mr. Benjamin H. Davis | Senior Vice President of Business Development & Strategy | 1964 |
| Ms. Marna I. Bronfen-Moore | Senior Vice President of Human Resources | 1968 |
| Mr. Chad T. Campbell | Senior VP and GM of Oncology & Interventional Devices | 1971 |
| Ms. Kim L. Seabury | Senior Vice President of Information Technology | 1968 |
Fundamentals
Valuation
Market cap$640.24M
Price-to-sales ratio1.97
Price-to-book value3.70
Price-earnings ratio-17.20
Return on Equity-18.00%
Return on Sales-10.00%
Return on Assets-12.00%
PEG ratio1.41
Earnings Per Share
Earnings Per Share$-0.88
Income Statement
Average volume412,812
EBITDA$-6.33M
1 year high (52w)$16.29
1 year low (52w)$9.39
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$19.50
Est return
31.40%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +11.0 | +8.7 | -12.3 | +8.2 | ||||||||
| 2022 | -25.8 | +10.4 | -10.2 | -6.5 | -7.1 | -1.6 | +16.1 | -5.0 | -5.0 | -31.0 | -8.0 | +8.2 |
| 2023 | -2.6 | -7.3 | -17.4 | -15.8 | +10.0 | +8.2 | -15.8 | -6.6 | -5.4 | -16.7 | +4.5 | +14.3 |
| 2024 | -26.5 | -8.7 | +6.7 | -0.7 | +9.0 | -5.5 | +37.1 | -4.2 | +6.3 | -12.3 | +3.7 | +28.3 |
| 2025 | +27.1 | -15.9 | +0.8 | -3.8 | +11.0 | +2.3 | -6.9 | +19.9 | +6.8 | +8.7 | +4.8 | -1.0 |
| 2026 | -18.3 | +9.8 | +0.1 | -8.4 | +2.9 | +19.2 | +13.1 | +6.3 | -2.3 |



